Shuwen Han | Microbial Pathogenesis and Virulence | Best Researcher Award

Posted on by Infectious

Best Researcher Award

Shuwen Han
Tarim University, China

Shuwen Han
Affiliation Tarim University
Country China
Scopus ID 56089782700
Documents 117
Citations 2,323
h-index 27
Subject Area Microbial Pathogenesis and Virulence
Event International Research Awards on Infectious Diseases
ORCID 0000-0001-6180-9565

The Best Researcher Award recognizes distinguished scholarly achievement, sustained scientific productivity, and impactful contributions to infectious disease research. Shuwen Han of Tarim University has established a significant academic profile through extensive publication activity, citation performance, and research focused on microbial pathogenesis, host–pathogen interactions, and virulence mechanisms. The researcher’s documented output and influence within microbiology and infectious disease studies provide a basis for evaluating suitability for recognition within the International Research Awards on Infectious Diseases.[1]

Abstract

Shuwen Han is an academic researcher affiliated with Tarim University whose scholarly work primarily addresses microbial pathogenesis, bacterial virulence, infectious disease mechanisms, and host–microbe interactions. With more than one hundred indexed publications and over two thousand citations, the researcher has contributed to the advancement of microbiological knowledge through experimental investigations and collaborative studies. The documented research portfolio demonstrates consistent scientific productivity, international visibility, and measurable influence within the infectious disease community. These achievements support consideration for the Best Researcher Award at the International Research Awards on Infectious Diseases and reflect sustained commitment to scientific excellence and knowledge dissemination.[1][2]

Keywords

Microbial Pathogenesis, Virulence Factors, Infectious Diseases, Microbiology, Host–Pathogen Interactions, Scientific Impact, Citation Analysis, Research Excellence.

Introduction

Research in infectious diseases remains essential for understanding pathogen biology, disease transmission, and public health challenges. Scientists working in microbial pathogenesis contribute valuable evidence for improving diagnostics, prevention strategies, and therapeutic interventions. Within this context, Shuwen Han has developed a research portfolio emphasizing mechanisms of bacterial virulence and microbial behavior, generating findings that support broader scientific understanding and future biomedical applications.[2]

Research Profile

The research profile of Shuwen Han reflects sustained academic productivity and recognized scientific influence. Indexed publication records indicate extensive engagement in microbiology and infectious disease research. Citation metrics and h-index values suggest that published findings have been referenced by researchers across related disciplines, demonstrating both visibility and scholarly relevance within the scientific literature.[1]

Research Contributions

Shuwen Han has contributed to investigations involving bacterial pathogenicity, virulence determinants, microbial adaptation, and disease-related biological processes. The research outputs support a deeper understanding of how microorganisms interact with hosts and environmental conditions. Such contributions are relevant to ongoing efforts aimed at improving infectious disease management, microbial surveillance, and translational microbiological research.[3]

Publications

The publication portfolio includes peer-reviewed articles addressing microbial pathogenesis, bacterial virulence mechanisms, infection biology, and related microbiological themes. Research outputs have appeared in recognized scientific journals and have contributed to scholarly discussions concerning pathogen behavior and disease development. The breadth of publications demonstrates ongoing participation in advancing infectious disease knowledge through evidence-based investigation.[2][4]

  • Microbial pathogenesis studies.
  • Virulence-related investigations.
  • Host–pathogen interaction research.
  • Infectious disease microbiology publications.

Research Impact

Research impact may be assessed through publication productivity, citation performance, and influence on subsequent scientific studies. With more than 2,300 citations and an h-index of 27, Shuwen Han demonstrates measurable academic impact. These indicators suggest that the researcher’s findings have contributed to ongoing scientific dialogue and have informed further investigations in microbiology and infectious diseases.[1]

Award Suitability

Evaluation for the Best Researcher Award typically considers originality, publication record, citation influence, disciplinary relevance, and contributions to scientific advancement. Based on available scholarly indicators, Shuwen Han demonstrates qualifications aligned with these criteria. The combination of extensive research output, recognized citation performance, and specialization in infectious disease-related microbiology supports consideration for academic recognition within an international award framework.[1][5]

Conclusion

Shuwen Han has established a notable research profile characterized by consistent publication activity, significant citation performance, and contributions to microbial pathogenesis and virulence research. The documented scholarly achievements reflect sustained engagement in advancing infectious disease knowledge. Based on academic metrics and research relevance, the researcher presents a strong case for consideration within the Best Researcher Award category of the International Research Awards on Infectious Diseases.[1]

References

  1. Elsevier. (n.d.). Scopus author details: Shuwen Han, Author ID 56089782700. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=56089782700
  2. ORCID. (n.d.). ORCID profile of Shuwen Han.
    https://orcid.org/0000-0001-6180-9565
  3. Future Microbiology. (2022). Bacterial imaging in tumour diagnosis.
    https://doi.org/10.1111/1751-7915.14474
  4. Journal of Translational Medicine. (2025). Dissolving microneedles enabled delivery of Oxaliplatin- sodium butyrate loaded outer membrane vesicles against rectal cancer.
    https://doi.org/10.1186/s12967-025-06921-5
  5. International Research Awards on Infectious Diseases. (n.d.). Award criteria and evaluation guidelines.
    https://infectious-diseases-conferences.pencis.com/

Nominee | Subject Area | Award Category

Posted on by Infectious

Your Nomination Has Been Selected

Congratulations. Your nomination has been officially approved and selected.
Award profile publication, certification, and verification services
are enabled only after successful registration.

Important: This page is published for registration purposes only.
Public announcement and verification services will be activated after registration.

Free Services Included

  • Nomination acknowledgement
  • Expert review process
  • Published award winners announcement list –

    View list
  • A dedicated nominee details page for verification purposes –

    Sample page

Registration Benefits (Select as You Wish)

  • Profile publication –

    Sample
  • Certification and verification services –

    Sample
  • Printed certificate by post
  • Printed momento by post
  • Online e-certificate download (any time)
  • QR-code verified certificate linked to a public verification page
  • Media posts publication
  • Winners promotional video publication
  • Award event celebrations
  • Global award indexing


Register Here

Digital credentials are typically available within 2–3 working days after registration.
Printed certificates and mementos are dispatched within
30–45 days via secure international air post.

Xin Su | Infectious Diseases | Best Researcher Award

Posted on by Infectious

Dr. Xin Su | Infectious Diseases | Best Researcher Award

Attending Physician | Nanjing University | China

Professor Xin Su, M.D., Ph.D., is a distinguished clinical scientist and Chief Physician renowned for his pioneering contributions to respiratory and critical care medicine, with particular expertise in the study and management of severe pulmonary infections. Over a distinguished career spanning nearly three decades, he has demonstrated an exceptional ability to bridge clinical excellence with translational research innovation. His work focuses on the pathogenesis, diagnosis, and treatment of invasive pulmonary aspergillosis (IPA) in non-neutropenic patients, a challenging and underexplored domain of pulmonary medicine. As a leading investigator, Professor Su has spearheaded multicenter studies that have transformed the understanding of pulmonary fungal infections, combining rigorous clinical observation with the use of novel diagnostic technologies, including machine learning and metagenomic sequencing. His publications in high-impact journals such as The Lancet Infectious Diseases, Microbiology Spectrum, Frontiers in Cellular and Infection Microbiology, and Clinical Microbiology and Infection reflect a deep commitment to advancing evidence-based practices and diagnostic accuracy in the field. Through his groundbreaking studies, Professor Su has introduced innovative diagnostic models that integrate big data analytics with clinical biomarkers, offering more precise and timely identification of IPA and related fungal diseases. Beyond diagnostics, his investigations into host immune responses, interferon signaling, and biomarker development have opened new avenues for prognostic assessment and personalized treatment strategies. His leadership roles as a Chief Physician, Professor, and Doctoral Supervisor at Nanjing University-affiliated hospitals underscore his dual impact as both a clinician and academic mentor. Colleagues and collaborators recognize his unique ability to unite global expertise, as evidenced by his participation in international research consortia addressing fungal infections and severe pneumonia outcomes. His scholarly rigor, coupled with his mentorship of young clinicians and researchers, has significantly enriched the field of respiratory and infectious disease research. While Professor Su’s scientific achievements are substantial, he continues to identify strategic growth areas that align with the evolving challenges of respiratory medicine. Expanding the clinical utility of machine learning-based diagnostic platforms, validating novel biomarkers in diverse patient populations, and enhancing global collaborative networks remain key objectives. Moreover, strengthening translational pathways that connect molecular diagnostics to frontline patient care is an ongoing priority, ensuring that innovations in the laboratory translate into improved clinical outcomes. Looking ahead, Professor Su’s future research aims to deepen the mechanistic understanding of host-pathogen interactions in fungal and viral co-infections, refine AI-driven diagnostic algorithms for pulmonary infections, and integrate multi-omics data into clinical decision-making frameworks. His vision is to establish an internationally recognized precision-medicine model for diagnosing and managing severe respiratory infections, ultimately contributing to reduced mortality, optimized therapeutic strategies, and global health resilience in the era of emerging respiratory pathogens. He has 2677 citations from 128 documents with an h-index of 28.

Profiles: Scopus | ORCID

Publications

1. Diagnostic and prognostic roles of interferon-λ1 and interferon-λ3 in bronchoalveolar lavage fluid and plasma in non-neutropenic patients with invasive pulmonary aspergillosis. (2025). Microbiology Spectrum.

2. Rapid and accurate diagnosis of severe pneumonia: Similarities and differences between severe community-acquired pneumonia and hospital-acquired pneumonia/ventilator-associated pneumonia. (2025). Chinese Journal of Tuberculosis and Respiratory Diseases.

3. Development and validation of a machine learning-based diagnostic model for identifying nonneutropenic invasive pulmonary aspergillosis in suspected patients: A multicenter cohort study. (2025). Microbiology Spectrum.

4. Expert consensus on cancer treatment-related lung injury. (2025). Journal of Thoracic Disease.

5. Pentraxin-3 as a novel prognostic biomarker in non-neutropenic invasive pulmonary aspergillosis patients. (2025). Microbiology Spectrum.